Skip to main content
ERAS
NASDAQ Life Sciences

Erasca Lands BMS Collaboration to Test ERAS-0015 With Navlimetostat in Pancreatic Cancer

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$13.99
Mkt Cap
$4.875B
52W Low
$2.52
52W High
$24.28
52W Position info
455% above low
Off High info
42% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

ERAS has more than doubled off its 52-week low of $2.52.

Summary

Erasca signed a clinical trial collaboration and supply agreement with Bristol Myers Squibb to test its pan-RAS molecular glue ERAS-0015 alongside BMS's investigational PRMT5 inhibitor navlimetostat (BMS-986504) in MTAP-deleted pancreatic ductal adenocarcinoma. BMS will sponsor and run the Phase 1/2 trial; Erasca supplies the drug and keeps commercial rights to ERAS-0015, with the arrangement mutually non-exclusive. The rationale is mechanistic: nearly all MTAP-deleted pancreatic tumors carry co-occurring RAS mutations, so hitting RAS and PRMT5 together could deepen responses in a cancer with few good options. For a clinical-stage company, a Big Pharma partner sponsoring a trial validates the asset and offloads cost, though Erasca gives up no rights and books no upfront cash here. This builds on the August FDA Fast Track designation for ERAS-0015 in metastatic pancreatic cancer and follows the Q3 report showing a $51.3M net loss against $947.8M in cash and securities. BMS is the larger party but the news is marginal to its pipeline; Erasca is the primary beneficiary.

At the time of this announcement, ERAS was trading at $13.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $2.52 to $24.28. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ERAS - Latest Insights

ERAS
Nov 12, 2026, 4:03 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $15.78
Real-time Price: $14.20 info
Change: -$1.58 (-10%) info
Market Cap: $4.875B info
ERAS
Nov 12, 2026, 4:01 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $15.78
Real-time Price: $14.20 info
Change: -$1.58 (-10%) info
Market Cap: $4.875B info
ERAS
Aug 24, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.11
Real-time Price: $14.20 info
Change: -$3.91 (-22%) info
Market Cap: $4.875B info
ERAS
Aug 24, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $18.11
Real-time Price: $14.20 info
Change: -$3.91 (-22%) info
Market Cap: $4.875B info
ERAS
Aug 11, 2026, 4:13 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $18.31
Real-time Price: $14.20 info
Change: -$4.11 (-22%) info
Market Cap: $4.875B info